Vascular Graft Solutions Acquires NEOGRAFT Technologies' Patent Portfolio to Advance Cardiovascular Disease Therapies

On January 6, 2020, VCBeat (WeChat ID: vcbeat) learned via PR Newswire that Israeli healthcare company Vascular Graft Solutions (VGS) announced the acquisition of several patent families from U.S. medical device company NeoGraft Technologies. The specific acquisition amount was not disclosed.

NEOGRAFT Technologies is a medical device company dedicated to developing technological equipment for coronary artery bypass grafting (CABG) surgery. Founded in 2009 and headquartered on the East Coast of the United States, its flagship product is Angioshield, a device designed to deliver controlled, temporary structural supports into veins intended for use as arteriovenous grafts. This product can be utilized for vascular reconstruction in both coronary and peripheral arteries.

The patents acquired by VGS include more than 25 patents in the United States, Europe, Canada, and Japan, including those developed and owned by Kips Bay Medical, a medical company that is a pioneer in the field of extravascular stents and vascular engineering.

This acquisition will expand VGS’s existing portfolio and support the maintenance of technologies developed and commercialized by the company, including those for coronary artery bypass grafting, peripheral vascular reconstruction, and high-flow arteriovenous (AV) fistulas. Following the completion of the acquisition, VGS plans to leverage new patents and resources to develop novel approaches for treating cardiovascular diseases, with a commitment to improving outcomes in cardiovascular surgical procedures and patient care.

Eyal Orion, Founder and CEO of VGS, stated, “These new patents and proprietary technologies were developed through joint research by renowned cardiac surgeon Professor Peter Zilla and his team. This will enable us to explore novel approaches to creating blood vessels for the treatment of atherosclerosis. This acquisition strengthens our IP portfolio, and combined with our existing clinical data, positions VGS as a global leader in the field of vascular engineering.”

Prior to its acquisition, NEOGRAFT Technologies completed six rounds of financing, raising a total of $39.3 million. The most recent round occurred on January 26, 2017, with a transaction amount of $5 million.

Vascular Graft Solutions (VGS), founded in 2009 and headquartered in Tel Aviv, Israel, is a company dedicated to the development and commercialization of innovative medical solutions. VGS’s flagship product, VEST (Venous External Support Technology), is an external device support designed to extend the lifespan of venous grafts by optimizing hemodynamics and mitigating graft-related diseases. After receiving CE approval in 2014, VGS entered the international market, with sales points freely available in the United Kingdom, Germany, Italy, Belgium, Israel, Switzerland, Greece, and South Africa. Currently, its marketing efforts are primarily focused on Europe.

(Compiled by: Yang Xiaohui)